{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:31:41Z","timestamp":1791919901936,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T11:58:04Z","timestamp":1535025484000},"page":"105527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-2915","authenticated-orcid":false,"given":"Jenny","family":"Bischoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0001","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"issue":"1 Suppl","key":"10.1016\/j.ijantimicag.2018.08.019_bib0002","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0003","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hiv.12600","article-title":"Highlights of the 2017 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons version 9.0","volume":"19","author":"Ryom","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0006","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD\u2013IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0007","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0010","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0013","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0014","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/ciw567","article-title":"Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV\u2013HCV-coinfected individuals: results from the German Hepatitis C Cohort (GECCO-01)","volume":"63","author":"Ingiliz","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/cid\/ciy220","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study","volume":"67","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0016","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0017","series-title":"The International Liver CongressTM 2018, 53rd Annual Meeting of the European Association for the Study of the Liver (EASL); 11\u201315 April 2018","article-title":"Retreatment of hepatitis C virus infection in patients who failed glecaprevir\/pibrentasvir","author":"Wyles","year":"2018"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0018","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV\/HCV in the real world?","volume":"62","author":"Saeed","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0019","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15284336.2017.1330801","article-title":"HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study","volume":"18","author":"Neukam","year":"2017","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/QAD.0000000000001699","article-title":"Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients","volume":"32","author":"Minguez","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jhep.2017.02.012","article-title":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients\u2014French ANRS CO13 HEPAVIH cohort","volume":"67","author":"Piroth","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0022","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/cid\/cix1004","article-title":"High treatment uptake in human immunodeficiency virus\/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.29814","article-title":"All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus\/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings","volume":"68","author":"Berenguer","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/hiv.12579","article-title":"Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?","volume":"19","author":"Bischoff","year":"2018","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0025","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/cid\/cix111","article-title":"Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus\/hepatitis C virus genotype 1-coinfected patients treated in routine practice","volume":"64","author":"Bhattacharya","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx062","article-title":"Highly successful hepatitis C virus (HCV) treatment outcomes in human immunodeficiency virus\/HCV-coinfected patients at a large, urban, Ryan White Clinic","volume":"4","author":"Patel","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0027","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/QAD.0000000000001465","article-title":"Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection","volume":"31","author":"Montes","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0028","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/cid\/ciw846","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir combination treatment in patients with HIV\/HCV co-infection: results of an Italian compassionate use program","volume":"64","author":"Massimo","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0029","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3851\/IMP3061","article-title":"Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials","volume":"22","author":"Arias","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx158","article-title":"Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus\/human immunodeficiency virus coinfection","volume":"4","author":"Boesecke","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0031","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among Black and nonBlack human immunodeficiency virus-infected adults in an urban center","volume":"66","author":"Falade-Nwulia","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0032","unstructured":"Boesecke C, M\u00fcller Mart\u00ednez E, Nelson M, Ingiliz P, Lutz T, Scholten S, et al. Fueling the epidemic: low rates of spontaneous clearance of acute HCV coinfection. In: 25th Conference on Retroviruses and Opportunistic Infections (CROI); 4\u20137 March 2018; Boston, MA."},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0033","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1473-3099(16)30408-X","article-title":"Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study","volume":"17","author":"Deterding","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0034","series-title":"68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 20\u201324 October","article-title":"100% SVR with 8 weeks of ledipasvir\/sofosbuvir in HIV-infected men with acute HCV infection: results from the SWIFT-C Trial (sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals)","author":"Naggie","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0035","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1097\/QAD.0000000000000834","article-title":"Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men","volume":"29","author":"Hagan","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2017.03.038","article-title":"Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990\u20132014","volume":"67","author":"van Santen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0037","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/cid\/cix1007","article-title":"Declining hepatitis C virus (HCV) incidence in Dutch human immunodeficiency virus-positive men who have sex with men after unrestricted access to HCV therapy","volume":"66","author":"Boerekamps","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0038","series-title":"25th Conference on Retroviruses and Opportunistic Infections (CROI); 4\u20137 March","article-title":"Swiss HIV Cohort Study. A treatment as prevention trial to eliminate HCV in HIV+ MSM: The Swiss HCVree trial","author":"Braun","year":"2018"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0039","doi-asserted-by":"crossref","unstructured":"Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc 2018;21(Suppl 2):e25062.","DOI":"10.1002\/jia2.25062"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/QAD.0000000000001263","article-title":"The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands","volume":"31","author":"Newsum","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0041","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","article-title":"HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe","volume":"66","author":"Ingiliz","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0043","doi-asserted-by":"crossref","unstructured":"Christensen S, Buggisch P, Mauss S, Boker KHW, Schott E, Klinker H, et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice? Addiction 2018;113:868\u201382.","DOI":"10.1111\/add.14128"},{"key":"10.1016\/j.ijantimicag.2018.08.019_bib0044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2017.03.047","article-title":"Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials","volume":"153","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T14:02:41Z","timestamp":1751810561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918302450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857918302450"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.019","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are there any challenges left in hepatitis C virus therapy of HIV-infected patients?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105527"}}